Updated:
Haohai Biological Technology
Haohai Biological Technology was established in Shanghai in 2007 by a medical-sector team including Jiang Wei, who continues to serve as General Manager.
Haohai Biological Technology
Haohai Biological Technology was established in Shanghai in 2007 by a medical-sector team including Jiang Wei, who continues to serve as General Manager. Unlike a pure-play investor, the company functions as an integrated developer and commercializer of biomaterials, built around hyaluronic acid technology platforms that it scaled from laboratory research to mass production. The firm listed in Hong Kong in 2015 and added a STAR Market listing in Shanghai in 2019, creating a rare dual-exchange footprint for a biomedical enterprise. Investment and capital deployment flow through internal product development and selective acquisitions rather than fund structures. The company's pipeline spans four therapeutic areas: ophthalmology products including intraocular lenses and viscoelastics; orthopedic injectables for joint repair; medical aesthetics such as dermal fillers; and surgical anti-adhesion gels. Acquisition activity includes the purchase of Contamac, a UK-based specialty lens material producer, and a portfolio of intraocular lens technologies that expanded the ophthalmology division into Western markets. Manufacturing and distribution reach across China, the United States, and the United Kingdom. Total headcount and assets under management do not appear in public disclosures for an investment arm distinct from the operating company. Corporate filings reflect revenue-driven growth, with the ophthalmology segment generating the majority of reported income in recent periods. There is no separately branded family office or asset management vehicle publicly associated with the firm, though the dual-listed structure suggests governance complexity that can accommodate both operating and strategic capital allocation functions. The structural differentiator is the dual-listing architecture paired with vertical integration. Haohai controls R&D, regulatory approval pipelines, manufacturing, and distribution for its biomaterial products, a chain that most biotech firms outsource. This integration allows retained earnings to cycle directly into next-generation product development without intermediary fund cycles, giving the firm a pace of capital redeployment uncommon in the sector. Succession planning and major shareholder composition remain opaque in English-language disclosures.
General information
Firm type
Asset Manager
Year founded
2007
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Shanghai
Corporate office
Shanghai, China
Principals
Jiang Wei
General Manager
Sector focus
Frequently asked questions
What does Haohai Biological Technology produce, and how does that relate to its investment activity?
The company develops and sells biomaterial products based primarily on hyaluronic acid technology. Its product lines cover ophthalmology (intraocular lenses, viscoelastics), orthopedics (joint lubricants), medical aesthetics (dermal fillers), and surgical anti-adhesion gels. Investment occurs through internal R&D funding and strategic acquisitions, such as the purchase of UK-based Contamac, rather than through external fund commitments.
Is Haohai Biological Technology a single family office, an operating company, or a venture investor?
Haohai functions as an operating biomedical company listed on public exchanges. There is no publicly identified separate family office or asset management division. Capital allocation decisions appear embedded within the corporate structure, directed toward product development and company acquisitions rather than passive third-party fund investments.
On which exchanges is Haohai Biological Technology listed, and why does that matter?
The company listed on the Hong Kong Stock Exchange in 2015 (ticker: 6826) and on the Shanghai STAR Market in 2019 (ticker: 688366). Dual listing on a major Asian exchange and a mainland Chinese tech-focused board is unusual for a biomedical firm and provides access to distinct investor bases and capital pools across onshore and offshore China.
What markets does Haohai Biological Technology serve geographically?
Haohai's primary revenue base is in China, but the company has expanded internationally. The acquisition of Contamac gave it a manufacturing and distribution presence in the United Kingdom, and its intraocular lens products reach the United States and other Western markets. The firm maintains a registered office in Shanghai, with additional operational footprints tied to acquired subsidiaries.
Who holds decision-making authority at Haohai Biological Technology?
Jiang Wei serves as General Manager and is associated with the firm's founding in 2007. As a publicly listed company, ultimate governance rests with a board of directors and shareholders, though detailed English-language disclosures on principal shareholders and investment committee composition are limited.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: